ASCO 2023 | The role of biomarkers in guiding treatment for early-stage breast cancer

Justin Balko, PharmD, PhD, Vanderbilt University Medical Center, Nashville, TN, discusses deploying biomarkers in early-stage breast cancer. The NeoPACT trial (NCT03639948) of pembrolizumab and chemotherapy in patients with early-stage triple negative breast cancer attempted to elucidate novel biomarkers of response in this setting. The FinHer Trial (ISRCTN76560285) of trastuzumab for HER2 positive breast cancer revealed that tumor infiltrating lymphocytes (TILs) did not correlate to a reduction in recurrence with trastuzumab. The PHERGain trial (NCT03161353) of trastuzumab and pertuzumab additionally demonstrated the utility of PET scans to potentially spare certain patients from chemotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.